Denali Therapeutics Inc. (DNLI) Financial Statements (2024 and earlier)

Company Profile

Business Address 161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,034,5111,336,215865,4071,469,697415,356464,297
Cash and cash equivalents127,106218,044293,477507,14479,44977,123
Short-term investments907,4051,118,171571,930962,553335,907387,174
Receivables   1,2265,674 1,182
Prepaid expense      1,350
Other undisclosed current assets29,62636,10430,60120,28414,67514,007
Total current assets:1,064,1371,372,319897,2341,495,655430,031480,836
Noncurrent Assets
Operating lease, right-of-use asset26,04830,43730,74332,61833,923
Property, plant and equipment45,58944,08738,86540,84646,73225,162
Long-term investments and receivables  425,44932,69939,886147,881
Long-term investments  425,44932,69939,886147,881
Other noncurrent assets18,14313,39911,8712,4622,6598,105
Total noncurrent assets:89,78087,923506,928108,625123,200181,148
TOTAL ASSETS:1,153,9171,460,2421,404,1621,604,280553,231661,984
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities77,9822,7904,7791,0712,59020,363
Employee-related liabilities   9,952
Accounts payable9,4832,7904,7791,0712,5901,891
Accrued liabilities68,499    8,520
Deferred revenue   27,91519,91418,739
Deferred rent credit      616
Other liabilities  66,69153,16547,14524,015380
Due to related parties4,388    
Contract with customer, liability11,427
Other undisclosed current liabilities 290,053292,3863,569  
Total current liabilities:77,982363,922378,24571,69945,34432,786
Noncurrent Liabilities
Long-term debt and lease obligation:   58,55464,17568,865 
Liabilities, other than long-term debt44,98153,4113,77724,02644,13282,353
Deferred revenue   3,39823,32543,753
Contract with customer, liability57,350
Deferred rent credit      24,532
Other liabilities  379379701379471
Operating lease, liability44,98153,03258,55464,17568,865
Other undisclosed noncurrent liabilities  4791,295293,849  
Total noncurrent liabilities:44,98153,89063,626382,050112,99782,353
Total liabilities:122,963417,812441,871453,749158,341115,139
Equity
Equity, attributable to parent1,030,9541,042,430962,2911,150,531394,890546,845
Common stock 1,7111,6861,5481,5311,2881,273
Additional paid in capital2,144,8112,018,6171,608,2381,503,660818,803774,158
Accumulated other comprehensive income (loss)643(6,886)(2,499)(245)350(649)
Accumulated deficit(1,116,211)(970,987)(644,996)(354,415)(425,551)(227,937)
Other undisclosed equity, attributable to parent      
Total equity:1,030,9541,042,430962,2911,150,531394,890546,845
TOTAL LIABILITIES AND EQUITY:1,153,9171,460,2421,404,1621,604,280553,231661,984

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues330,531108,46348,661335,65926,678129,160
Revenue from related parties3,2003,736307,437  
Gross profit:330,531108,46348,661335,65926,678129,160
Operating expenses(527,230)(449,207)(344,412)(272,941)(239,862)(175,532)
Other undisclosed operating income      
Operating income (loss):(196,699)(340,744)(295,751)62,718(213,184)(46,372)
Nonoperating income51,50514,7744,5959,24115,21910,132
Investment income, nonoperating43,9521,637(8,748)(55)5,0192,705
Income (loss) from continuing operations before income taxes:(145,194)(325,970)(291,156)71,959(197,965)(36,240)
Income tax expense (benefit) (30)(21)575823351 
Other undisclosed loss from continuing operations      
Income (loss) from continuing operations:(145,224)(325,991)(290,581)72,782(197,614)(36,240)
Income (loss) before gain (loss) on sale of properties:(290,581)72,782(197,614)(36,240)
Net income (loss):(145,224)(325,991)(290,581)72,782(197,614)(36,240)
Other undisclosed net income (loss) attributable to parent   (1,646)  
Net income (loss) available to common stockholders, diluted:(145,224)(325,991)(290,581)71,136(197,614)(36,240)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(145,224)(325,991)(290,581)72,782(197,614)(36,240)
Comprehensive income (loss):(145,224)(325,991)(290,581)72,782(197,614)(36,240)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent7,529(4,387)(2,254)(2,241)999(281)
Comprehensive income (loss), net of tax, attributable to parent:(137,695)(330,378)(292,835)70,541(196,615)(36,521)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: